There have been a few observational studies that have suggested there may be an increased risk of cancer while using glargine, a long acting insulin analogue.
There is a long term randomised controlled trial, Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, that should provide more evidence on this matter.
The current RGH e-Bulletin summarises the evidence from four observational studies.
Download the small file: Insulin glargine and associated cancer risk (214)
The 2009 RGH E-Bulletins are archived here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
{ 6 trackbacks }
{ 0 comments… add one now }